677 related articles for article (PubMed ID: 20933470)
1. Evaluation of the Mycobacterium smegmatis and BCG models for the discovery of Mycobacterium tuberculosis inhibitors.
Altaf M; Miller CH; Bellows DS; O'Toole R
Tuberculosis (Edinb); 2010 Nov; 90(6):333-7. PubMed ID: 20933470
[TBL] [Abstract][Full Text] [Related]
2. Resazurin reduction assays for screening of anti-tubercular compounds against dormant and actively growing Mycobacterium tuberculosis, Mycobacterium bovis BCG and Mycobacterium smegmatis.
Taneja NK; Tyagi JS
J Antimicrob Chemother; 2007 Aug; 60(2):288-93. PubMed ID: 17586560
[TBL] [Abstract][Full Text] [Related]
3. A novel screening method based on menadione mediated rapid reduction of tetrazolium salt for testing of anti-mycobacterial agents.
Singh U; Akhtar S; Mishra A; Sarkar D
J Microbiol Methods; 2011 Feb; 84(2):202-7. PubMed ID: 21129420
[TBL] [Abstract][Full Text] [Related]
4. Bactericidal activity of 2-nitroimidazole against the active replicating stage of Mycobacterium bovis BCG and Mycobacterium tuberculosis with intracellular efficacy in THP-1 macrophages.
Khan A; Sarkar S; Sarkar D
Int J Antimicrob Agents; 2008 Jul; 32(1):40-5. PubMed ID: 18538548
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of mycobacterial growth by plumbagin derivatives.
Mathew R; Kruthiventi AK; Prasad JV; Kumar SP; Srinu G; Chatterji D
Chem Biol Drug Des; 2010 Jul; 76(1):34-42. PubMed ID: 20456370
[TBL] [Abstract][Full Text] [Related]
6. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
7. Trichoderins, novel aminolipopeptides from a marine sponge-derived Trichoderma sp., are active against dormant mycobacteria.
Pruksakorn P; Arai M; Kotoku N; Vilchèze C; Baughn AD; Moodley P; Jacobs WR; Kobayashi M
Bioorg Med Chem Lett; 2010 Jun; 20(12):3658-63. PubMed ID: 20483615
[TBL] [Abstract][Full Text] [Related]
8. Loperamide exerts a direct bactericidal effect against M. tuberculosis, M. bovis, M. terrae and M. smegmatis.
Barrientos OM; Juárez E; Gonzalez Y; Castro-Villeda DA; Torres M; Guzmán-Beltrán S
Lett Appl Microbiol; 2021 Mar; 72(3):351-356. PubMed ID: 33220096
[TBL] [Abstract][Full Text] [Related]
9. Antimycobacterial evaluation and preliminary phytochemical investigation of selected medicinal plants traditionally used in Mozambique.
Luo X; Pires D; Aínsa JA; Gracia B; Mulhovo S; Duarte A; Anes E; Ferreira MJ
J Ethnopharmacol; 2011 Sep; 137(1):114-20. PubMed ID: 21571059
[TBL] [Abstract][Full Text] [Related]
10. Anti-dormant mycobacterial activity and target analysis of nybomycin produced by a marine-derived Streptomyces sp.
Arai M; Kamiya K; Pruksakorn P; Sumii Y; Kotoku N; Joubert JP; Moodley P; Han C; Shin D; Kobayashi M
Bioorg Med Chem; 2015 Jul; 23(13):3534-41. PubMed ID: 25934225
[TBL] [Abstract][Full Text] [Related]
11. Antimycobacterial activity of UDP-galactopyranose mutase inhibitors.
Borrelli S; Zandberg WF; Mohan S; Ko M; Martinez-Gutierrez F; Partha SK; Sanders DA; Av-Gay Y; Pinto BM
Int J Antimicrob Agents; 2010 Oct; 36(4):364-8. PubMed ID: 20678902
[TBL] [Abstract][Full Text] [Related]
12. Accumulation of rifampicin by Mycobacterium aurum, Mycobacterium smegmatis and Mycobacterium tuberculosis.
Piddock LJ; Williams KJ; Ricci V
J Antimicrob Chemother; 2000 Feb; 45(2):159-65. PubMed ID: 10660497
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Mycobacterium smegmatis as a possible surrogate screen for selecting molecules active against multi-drug resistant Mycobacterium tuberculosis.
Chaturvedi V; Dwivedi N; Tripathi RP; Sinha S
J Gen Appl Microbiol; 2007 Dec; 53(6):333-7. PubMed ID: 18187888
[TBL] [Abstract][Full Text] [Related]
14. The porin MspA from Mycobacterium smegmatis improves growth of Mycobacterium bovis BCG.
Sharbati-Tehrani S; Meister B; Appel B; Lewin A
Int J Med Microbiol; 2004 Oct; 294(4):235-45. PubMed ID: 15532981
[TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of mycobacterial NADH pyrophosphatase isoforms reveals a novel mechanism for isoniazid and ethionamide inactivation.
Wang XD; Gu J; Wang T; Bi LJ; Zhang ZP; Cui ZQ; Wei HP; Deng JY; Zhang XE
Mol Microbiol; 2011 Dec; 82(6):1375-91. PubMed ID: 22026918
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the construction of unmarked deletion mutations in Mycobacterium smegmatis, Mycobacterium bovis bacillus Calmette-Guérin, and Mycobacterium tuberculosis H37Rv by allelic exchange.
Pavelka MS; Jacobs WR
J Bacteriol; 1999 Aug; 181(16):4780-9. PubMed ID: 10438745
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of a novel antimycobacterial compound, N-octanesulfonylacetamide, and its effects on lipid and mycolic acid synthesis.
Parrish NM; Houston T; Jones PB; Townsend C; Dick JD
Antimicrob Agents Chemother; 2001 Apr; 45(4):1143-50. PubMed ID: 11257028
[TBL] [Abstract][Full Text] [Related]
18. Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
Arai M; Sobou M; Vilchéze C; Baughn A; Hashizume H; Pruksakorn P; Ishida S; Matsumoto M; Jacobs WR; Kobayashi M
Bioorg Med Chem; 2008 Jul; 16(14):6732-6. PubMed ID: 18556206
[TBL] [Abstract][Full Text] [Related]
19. Screening of antitubercular compound library identifies novel ATP synthase inhibitors of Mycobacterium tuberculosis.
Kumar S; Mehra R; Sharma S; Bokolia NP; Raina D; Nargotra A; Singh PP; Khan IA
Tuberculosis (Edinb); 2018 Jan; 108():56-63. PubMed ID: 29523328
[TBL] [Abstract][Full Text] [Related]
20. The abyssomicin C family as in vitro inhibitors of Mycobacterium tuberculosis.
Freundlich JS; Lalgondar M; Wei JR; Swanson S; Sorensen EJ; Rubin EJ; Sacchettini JC
Tuberculosis (Edinb); 2010 Sep; 90(5):298-300. PubMed ID: 20739223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
